ATS (ATS) Q2 2026: Nuclear Backlog Surges 154%, Rebalancing Growth Portfolio
ATS delivered a robust Q2, with a 154% increase in nuclear backlog positioning the company for outsized growth in energy relative to other segments. Life sciences and food & beverage remain resilient, while margin expansion is supported by cost realignment and operational discipline. Management’s focus on innovation and a healthy M&A funnel signals a continued push toward diversified, higher-value end markets.
Summary
- Nuclear Pipeline Transforms Portfolio: Record nuclear backlog signals ATS’s energy segment is becoming a core growth pillar.
- Margin Expansion Focus: Restructuring and operational leverage target improved profitability despite macro and funding headwinds.
- Innovation and M&A Remain Central: Illuminate platform rollout and active M&A pipeline reinforce ATS’s long-term competitive positioning.
Performance Analysis
ATS posted double-digit organic revenue growth, with total revenues up nearly 19% year-over-year, underpinned by a strong showing in life sciences, food & beverage, and energy. Organic growth accounted for 12.6% of the increase, supplemented by FX and M&A contributions. Notably, adjusted operating earnings rose 40%, reflecting both higher volumes and incremental margin expansion. Gross margin improved modestly, aided by disciplined execution and a focus on higher-value projects.
Order bookings were essentially flat year-over-year, but backlog reached $2.1 billion—up 14% from last year— providing strong revenue visibility. The book-to-bill ratio held at a healthy 1.12, with all verticals at or above parity, signaling ongoing demand resilience. Cash flow from operations was positive, and working capital intensity remains a focus as the company targets a 15% exit rate, down from 18.3% at quarter-end.
- Energy Backlog Acceleration: Nuclear backlog jumped 154% to $277 million, now ATS’s second-largest segment by backlog.
- Life Sciences Stability: Life sciences backlog at $1.1 billion, with GLP-1 drug delivery and radiopharma driving opportunity.
- Cost Structure Realignment: $15 million restructuring targets sub-annual payback and future margin expansion.
Segment mix is shifting: Energy’s rapid growth is offsetting slower momentum in transportation and some government-funded life sciences sub-segments. Services, with their recurring revenue profile, continue to anchor overall stability.
Executive Commentary
"Order backlog of approximately $2.1 billion continues to provide good revenue visibility. Our opportunity funnel remains healthy and well-diversified... Momentum remains especially strong in the radiopharma space, supported by investments in production capacity and the advancement of new therapeutics."
Ryan McLeod, Interim Chief Executive Officer
"We estimate restructuring costs of approximately $15 million will be incurred in the final half of this fiscal year with an expected payback of less than one year... There is no change to our expectations for full-year high single-digit revenue growth as previously disclosed. We continue to expect adjusted operating margin improvement on a full-year basis in fiscal 26."
Ann Sobolski, Interim Chief Financial Officer
Strategic Positioning
1. Energy Segment Emerges as Growth Engine
Nuclear projects have vaulted to the forefront, with backlog now at a record $277 million. ATS is leveraging its expertise in refurbishment, new reactor builds, and decommissioning—areas benefiting from policy tailwinds and data center-driven energy demand. Early-stage design work for small modular reactors (SMRs, compact nuclear reactors) positions ATS for future commercial deployment as the nuclear build-out accelerates.
2. Life Sciences: Diversification and Innovation
Life sciences remains the largest backlog contributor at $1.1 billion, with a broad mix across radiopharma, autoinjectors, wearables, and automated pharmacies. GLP-1 drug delivery (therapies for diabetes/obesity) is stable at roughly 20% of life sciences backlog. ATS’s ability to serve both single-use and emerging multi-dose autoinjector formats, as well as the expanding radiopharma market, underpins segment durability. The new Coma Chair Competence Center strengthens regional service and project execution in North America.
3. Operational Discipline and Working Capital Focus
Margin expansion is underpinned by a multi-pronged approach: cost realignment, SG&A leverage, and continuous improvement via the ATS Business Model (ABM, ATS’s proprietary operational excellence framework). Working capital initiatives are targeting a reduction to 15% of revenue, with improvement expected as milestone billings and collections normalize through year-end.
4. M&A and Innovation as Strategic Levers
The M&A funnel remains active, but management is balancing new deals with a commitment to bring leverage back within the 2-3x target range. Recent U.S. listing enhances share currency for future acquisitions. The Illuminate Manufacturing Intelligence platform (factory analytics and integration software) is being deployed across more businesses, driving equipment integration and data-driven value for customers.
5. Decentralized Model and Leadership Transition
ATS’s decentralized structure is credited for execution consistency during the CEO transition. The board’s ongoing search for a permanent CEO has not disrupted operational focus, with senior leadership advancing growth priorities and embedding ABM discipline across the firm.
Key Considerations
This quarter marks a strategic rebalancing for ATS: Energy’s rapid expansion is shifting the company’s revenue mix, while life sciences and food & beverage maintain solid growth. Margin improvement is underpinned by both revenue growth and structural cost actions.
Key Considerations:
- Nuclear Backlog as a Growth Catalyst: Energy’s share of backlog is rising, with multi-year revenue implications as refurbishment and new build projects ramp.
- Services Recurrence Anchors Stability: Service revenue, with its recurring nature, is performing strongly and remains a strategic focus for long-term growth.
- Restructuring to Drive Margin Expansion: $15 million in targeted cost actions are expected to generate rapid payback and reinvestment capacity in innovation and high-growth segments.
- Working Capital Execution Remains Critical: Achieving the 15% working capital target will be key for free cash flow and balance sheet flexibility, especially as large projects cycle through billing milestones.
- Leadership Continuity Amid Transition: Decentralized operations and embedded ABM culture are sustaining performance while the CEO search continues.
Risks
Backlog conversion timing and project delivery remain vulnerable to milestone delays, especially in large, multi-year nuclear and life sciences contracts. Macroeconomic and geopolitical risks—including trade, tariffs, and funding changes in government-backed life sciences—could impact demand and margin realization. Leverage reduction is a priority, but any slippage in cash generation or working capital could constrain M&A flexibility or delay deleveraging targets.
Forward Outlook
For Q3, ATS guided to:
- Revenue of $700 million to $740 million
For full-year 2026, management maintained guidance:
- High single-digit total revenue growth
- Year-over-year adjusted operating margin expansion
Management is prioritizing margin improvement, working capital efficiency, and leverage reduction for the remainder of the year, with incremental cost savings from restructuring to be partially reinvested in innovation and growth verticals.
- Order backlog and funnel activity in energy and life sciences remain strong
- CapEx and intangible investment expected to be $80–$100 million for the year
Takeaways
ATS’s strategic pivot toward energy, especially nuclear, is reshaping its growth profile and backlog composition. Margin expansion is being driven by both scale and cost actions, while recurring service revenue and innovation investment provide ballast against cyclical headwinds.
- Energy Segment Upside: Nuclear backlog growth is set to drive multi-year revenue expansion and margin stability as new build and refurbishment projects convert.
- Margin and Cash Discipline: Cost realignment and SG&A leverage are critical to delivering on margin expansion and deleveraging commitments.
- Innovation and M&A Watch: Continued investment in manufacturing intelligence and a healthy deal pipeline position ATS for future portfolio enhancements.
Conclusion
ATS’s Q2 results underscore a portfolio in transition, with energy’s outsized growth balancing more mature or cyclical segments. Leadership’s operational discipline and focus on innovation reinforce the company’s ability to navigate end market shifts and deliver on long-term value creation.
Industry Read-Through
ATS’s nuclear backlog surge is a leading indicator for automation and engineering firms exposed to the global energy transition, particularly in clean nuclear infrastructure. The resilience of recurring service revenue highlights the growing importance of aftermarket and digital solutions in automation. For peers in life sciences equipment and factory automation, the shift toward diversified, regulated end markets and recurring revenue streams is a durable theme, especially as macro and funding uncertainty persists. The continued emphasis on operational excellence and working capital efficiency will be a key differentiator for industry players navigating large project cycles and evolving customer demand.